Call for action on antimicrobial resistance
21 August 2013
International leaders from the pharmaceutical industry, academia,
SMEs and the healthcare sector met in May to look at why we are no
closer to defusing the antibiotic resistance “ticking-time bomb”
than we were a decade ago.
The report of this meeting  1. makes it clear that the
research and development landscape must change, that the time for
action is now and that numerous new collaborative cross sector
research programmes are required. To achieve these significant
additional funding across the globe is required.
Progress will be quicker if the academic, biotechnology research
and industry establish mechanisms to collaborate within a
precompetitive space. There is a role for national funding agencies
in this process, but proper due diligence of the proposed research
must be carried out by experts in the field.
Professor Laura Piddock, Director of Antibiotic Action said, “We
need to be inventive and innovative in addressing a problem of this
magnitude. The solutions are complex but achievable if we can learn
from what has gone before. We must identify ways for groups to work
together in precompetitive space or under open innovation principles
and also move quickly to more ambitious solutions, such as entirely
public sector-led initiatives. One thing is clear, we cannot stand
still”. Her words resonate loudly with The Wellcome Trust, Medical
Research Council and BBSRC, all of whom supported the meeting.
1. The Antibiotic Action report:
Lessons to be learnt from Pharma about discovery and development of
new antibacterial drugs